$
2.410
-0.05(-2.033%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.4855
Open
2.480
VWAP
2.40
Vol
99.29K
Mkt Cap
39.68M
Low
2.345
Amount
238.73K
EV/EBITDA(TTM)
--
Total Shares
44.12M
EV
-3.75M
EV/OCF(TTM)
--
P/S(TTM)
--
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-1.800
-68.42%
--
--
-1.600
-64.44%
--
--
-1.400
+16.67%
Estimates Revision
The market is revising No Change the revenue expectations for IN8bio, Inc. (INAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -57.57%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-57.57%
In Past 3 Month
3 Analyst Rating
up Image
3717.43% Upside
Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
3717.43% Upside
Current: 2.410
sliders
Low
36.00
Averages
92.00
High
180.00
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$8 → $6
2025-03-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2025-02-12
Reason
Jones Trading
Soumit Roy
Hold
to
Strong Buy
Upgrades
$1.2
2025-02-11
Reason
JonesResearch analyst Soumit Roy upgraded IN8bio to Buy from Hold with a $1.20 price target.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2024-11-26
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$13 → $8
2024-11-13
Reason
Jones Trading
Soumit Roy
Strong Buy
to
Hold
Downgrades
n/a
2024-08-12
Reason

Valuation Metrics

The current forward P/E ratio for IN8bio Inc (INAB.O) is -0.51, compared to its 5-year average forward P/E of -2.18. For a more detailed relative valuation and DCF analysis to assess IN8bio Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.18
Current PE
-0.51
Overvalued PE
-0.68
Undervalued PE
-3.68

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.24
Undervalued EV/EBITDA
-0.49

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.04
Undervalued PS
-0.04

Financials

Annual
Quarterly
FY2025Q1
YoY :
-34.53%
-5.66M
Operating Profit
FY2025Q1
YoY :
-35.18%
-5.55M
Net Income after Tax
FY2025Q1
YoY :
-65.00%
-0.07
EPS - Diluted
FY2025Q1
YoY :
-60.93%
-3.12M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2792.5% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

INAB News & Events

Events Timeline

2025-06-09 (ET)
2025-06-09
07:17:38
IN8bio recognizes 4-years in remission for patient treated with INB-200
select
2025-06-02 (ET)
2025-06-02
07:47:20
IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM
select
2025-05-14 (ET)
2025-05-14
08:11:33
IN8bio announces preclinical data from its INB-619 program
select
Sign Up For More Events

News

4.5
06-09Benzinga
US Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
9.0
06-02Newsfilter
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
9.0
05-14Newsfilter
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
Sign Up For More News

FAQ

arrow icon

What is IN8bio Inc (INAB) stock price today?

The current price of INAB is 2.41 USD — it has decreased -2.03 % in the last trading day.

arrow icon

What is IN8bio Inc (INAB)'s business?

arrow icon

What is the price predicton of INAB Stock?

arrow icon

What is IN8bio Inc (INAB)'s revenue for the last quarter?

arrow icon

What is IN8bio Inc (INAB)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for IN8bio Inc (INAB)'s fundamentals?

arrow icon

How many employees does IN8bio Inc (INAB). have?

arrow icon

What is IN8bio Inc (INAB) market cap?